Daxor (NASDAQ:DXR) Stock Price Up 6.7% – Time to Buy?

Shares of Daxor Corporation (NASDAQ:DXR) rose 6.7% on Tuesday . The stock traded as high as $10.41 and last traded at $10.14. 2,812 shares were traded during trading, an increase of 30% from the average session volume of 2,162 shares. The stock had previously closed at $9.50.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “hold (c)” rating on shares of Daxor in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

Daxor Trading Up 1.6%

The business has a fifty day simple moving average of $10.31 and a 200 day simple moving average of $11.50.

Daxor (NASDAQ:DXR) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.10) earnings per share for the quarter.

Institutional Trading of Daxor

A number of institutional investors and hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. bought a new position in shares of Daxor in the 2nd quarter worth about $86,000. Nano Cap New Millennium Growth Fund L P bought a new stake in shares of Daxor during the 4th quarter valued at about $184,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management acquired a new stake in Daxor during the first quarter worth about $245,000. Crescent Grove Advisors LLC bought a new position in Daxor in the first quarter worth about $104,000. Finally, Aristides Capital LLC bought a new position in Daxor in the first quarter worth about $403,000. 1.34% of the stock is owned by institutional investors and hedge funds.

About Daxor

Daxor Corporation is a medical diagnostics company focused on providing precise blood volume analysis to support patient management in critical care, surgical, cardiology and nephrology settings. The company’s core offering, the BVA?100 Blood Volume Analyzer, employs radiolabeled albumin techniques to deliver accurate measurements of total blood volume, red cell mass and plasma volume. By quantifying a patient’s fluid status, Daxor aims to help clinicians tailor therapies for conditions such as anemia, heart failure and fluid overload.

In addition to the BVA?100 analyzer, Daxor supplies reagent kits, calibration standards and software for data analysis and reporting.